W. Howe

发表

Techniques for perception by a computer of synthetically significant structural features in complex molecules

W. T. Wipke, R. Cramer, E. Corey, 1972 .

General methods of synthetic analysis. Strategic bond disconnections for bridged polycyclic structures

G. A. Petersson, E. Corey, W. Howe, 1975 .

Computer-assisted synthetic analysis. Facile man-machine communication of chemical structure by interactive computer graphics

W. T. Wipke, R. Cramer, E. Corey, 1972 .

Computer-Assisted Organic Synthesis

W. T. Wipke, W. Howe, W. Wipke, 1977 .

Prediction of the Tertiary Structure of the β-Secretase Zymogen☆

Kuo-Chen Chou, K. Chou, W. Howe, 2002 .

Recent advances in de novo molecular design

Joseph B. Moon, W. Howe, J. Moon, 1993 .

Computer design of bioactive molecules: A method for receptor‐based de novo ligand design

W. Howe, J. Moon, W. Jeffrey Howe, 1991, Proteins.

Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors.

B C Finzel, K D Watenpaugh, W. Howe, 1996, Journal of medicinal chemistry.

Computer-assisted synthetic analysis. Methods for machine generation of synthetic intermediates involving multistep look-ahead

David A. Pensak, E. Corey, W. Howe, 1974 .

Computer-assisted synthetic analysis for complex molecules. Methods and procedures for machine generation of synthetic intermediates

Richard D. Cramer, R. Cramer, E. Corey, 1972 .

Cycloalkylpyranones and cycloalkyldihydropyrones as HIV protease inhibitors: exploring the impact of ring size on structure-activity relationships.

W. Howe, D. Anderson, K. Chong, 1996, Journal of medicinal chemistry.

Use of medium-sized cycloalkyl rings to enhance secondary binding: discovery of a new class of human immunodeficiency virus (HIV) protease inhibitors.

W. Howe, B. Finzel, K. Watenpaugh, 1995, Journal of medicinal chemistry.

Peptidomimetic Inhibitors of Human Immunodeficiency Virus Protease ( HIV‐PR): Design, Enzyme Binding and Selectivity, Antiviral Efficacy, and Cell Permeability Properties.

D. Decamp, C. Craik, W. Lowther, 1995 .

General methods of synthetic analysis. Strategic bond disconnections for bridged polycyclic structures

G. A. Petersson, E. Corey, W. Howe, 1975 .

Structure-based design of novel HIV protease inhibitors: carboxamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent nonpeptidic inhibitors.

K D Watenpaugh, W. Howe, A. Tomasselli, 1995, Journal of medicinal chemistry.

Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.

K D Watenpaugh, W. Howe, D. Anderson, 1997, Journal of medicinal chemistry.

Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors.

W. Howe, K. Watenpaugh, R. Tommasi, 1996, Journal of medicinal chemistry.

Structure-based design of HIV protease inhibitors: 4-hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors.

K D Watenpaugh, W. Howe, K. Watenpaugh, 1994, Journal of medicinal chemistry.

Inhibitors of the protease from human immunodeficiency virus: synthesis, enzyme inhibition, and antiviral activity of a series of compounds containing the dihydroxyethylene transition-state isostere.

W. Howe, A. Tomasselli, R. Heinrikson, 1993, Journal of medicinal chemistry.

Structure-activity-relationship pertaining to the north-west region of the kappa opioid agonist, U-50,488

W. Howe, J. Szmuszkovicz, Shikai Zhao, 1994 .

Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.

W. Howe, K. Watenpaugh, M. Janakiraman, 1995, Journal of medicinal chemistry.

Structure-based design of nonpeptidic HIV protease inhibitors from a cyclooctylpyranone lead structure.

K D Watenpaugh, W. Howe, K. Watenpaugh, 1995, Journal of medicinal chemistry.

Protein binding chiral discrimination of HPLC stationary phases made with whole, fragmented, and third domain turkey ovomucoid.

W. M. Westler, W. Howe, E. Ulrich, 1995, Analytical chemistry.

Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2.

D. Decamp, C. Craik, W. Howe, 1990, The Journal of biological chemistry.

The HIV-1 protease as enzyme and substrate: mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties.

W. Howe, I. Reardon, C. Bannow, 1994, Biochemistry.

Inhibitors of the protease from human immunodeficiency virus: design and modeling of a compound containing a dihydroxyethylene isostere insert with high binding affinity and effective antiviral activity.

W. Howe, A. Tomasselli, R. Heinrikson, 1991, Journal of medicinal chemistry.

Crystal structure of a complex of HIV‐1 protease with a dihydroxyethylene‐containing inhibitor: Comparisons with molecular modeling

Narmada Thanki, Alexander Wlodawer, A. Wlodawer, 1992, Protein science : a publication of the Protein Society.

CXC Chemokines Connective Tissue Activating Peptide-III and Neutrophil Activating Peptide-2 are Heparin/Heparan Sulfate-degrading Enzymes (*)

W. Howe, I. Reardon, R. Heinrikson, 1995, The Journal of Biological Chemistry.

Computer Modeling of Constrained Peptide Systems

K. Chou, W. Howe, J. Blinn, 1992 .

Prediction of the tertiary structure of the beta-secretase zymogen.

Kuo-Chen Chou, K. Chou, W. Howe, 2002, Biochemical and biophysical research communications.

Molecular substructure searching: minicomputer-based query execution

Thomas R. Hagadone, T. R. Hagadone, W. J. Howe, 1982, J. Chem. Inf. Comput. Sci..

3D database searching and de novo construction methods in molecular design

Joseph B. Moon, W. Jeffrey Howe, W. Howe, 1990 .

The complexities of AIDS : an assessment of the HIV protease as a therapeutic target

A. Wlodawer, W. Howe, A. Tomasselli, 1991 .

Human immunodeficiency virus type‐1 reverse transcriptase and ribonuclease h as substrates of the viral protease

D B Evans, W. Howe, A. Tomasselli, 1993, Protein science : a publication of the Protein Society.

Calcium‐free calmodulin is a substrate of proteases from human immunodeficiency viruses 1 and 2

D. Decamp, C. Craik, W. Howe, 1991, Proteins.

Peptidomimetic inhibitors of human immunodeficiency virus protease (HIV-PR): Design, enzyme binding and selectivity, antiviral efficacy, and cell permeability properties

D. Decamp, C. Craik, W. Lowther, 1993 .

HIV protease (HIV PR) inhibitor structure-activity-selectivity, and active site molecular modeling of high affinity Leu [CH(OH)CH2]Val modified viral and nonviral substrate analogs.

T K Sawyer, W. Howe, A. Tomasselli, 2009, International journal of peptide and protein research.